Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404 · see citing works

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP

Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · see citing works

Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · see citing works

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,488 · see citing works

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · see citing works

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works

A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease

Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740 · see citing works

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701 · see citing works

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease

Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · see citing works

Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease

Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513 · see citing works

Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy

Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511 · see citing works

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works

Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P. A., Schenk, D., & Hyman, B. T. (2001) · Nature Medicine · doi:10.1038/85525 · Cited by 445 · see citing works

Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436 · see citing works

Reversible memory loss in a mouse transgenic model of Alzheimer’s disease

Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420 · see citing works

Disaggregation of Alzheimer β-amyloid by site-directed mAb

Solomon, B., Koppel, R., Frankel, D., & Hanan, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 420 · see citing works

Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis

McLaurin, J., Cecal, R., Kierstead, M. E., Tian, X., Phinney, A. L., Manea, M., French, J. E., Lambermon, M. H. L., Darabie, A. A., Brown, M. E., et al. (2002) · Nature Medicine · doi:10.1038/nm790 · Cited by 412 · see citing works

Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · see citing works

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., & Morgan, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-24 · Cited by 388 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β<i>In Vivo</i>by Immunotherapy

Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323 · see citing works

Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β

Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320 · see citing works

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

Boche, D., Zotova, E., Weller, R. O., Love, S., Neal, J. W., Pickering, R. M., Wilkinson, D., Holmes, C., & Nicoll, J. A. R. (2008) · Brain · doi:10.1093/brain/awn261 · Cited by 316 · see citing works

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

Solomon, B., Koppel, R., Hanan, E., & Katzav-Gozansky, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.452 · Cited by 314 · see citing works

Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D. H., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 298 · see citing works

Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles "Do Count" When Staging Disease Severity

Nelson, P. T., Jicha, G. A., Schmitt, F. A., Liu, H., Davis, D. G., Mendiondo, M. S., Abner, E. L., & Markesbery, W. R. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31815c5efb · Cited by 292 · see citing works

Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease

Höck, C., Konietzko, U., Papassotiropoulos, A., Wollmer, A., Streffer, J. R., von Rotz, R. C., Davey, G. E., Moritz, E., & Nitsch, R. M. (2002) · Nature Medicine · doi:10.1038/nm783 · Cited by 281 · see citing works

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

Cribbs, D. H. (2003) · International Immunology · doi:10.1093/intimm/dxg049 · Cited by 280 · see citing works

Aβ Species Removal After Aβ ₄₂ Immunization

Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265 · see citing works

Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse

Gordon, M. N., Holcomb, L. A., Jantzen, P. T., DiCarlo, G., Wilcock, D., Boyett, K. W., Connor, K., Melachrino, J., O'Callaghan, J. P., & Morgan, D. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7754 · Cited by 247 · see citing works

IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor

Deane, R., Sagare, A. P., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., & Zloković, B. V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3697-05.2005 · Cited by 233 · see citing works

Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · see citing works

Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet

Lemere, C. A., Beierschmitt, A., Iglesias, M., Spooner, E. T., Bloom, J. K., Leverone, J. F., Zheng, J. B., Seabrook, T. J., Louard, D., Li, D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63296-8 · Cited by 230 · see citing works

Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations

DeKosky, S. T., Harbaugh, R. E., Schmitt, F. A., Bakay, R. A. E., Chui, H. C., Knopman, D. S., Reeder, T. M., Shetter, A. G., Senter, H. J., Markesbery, W. R., et al. (1992) · Annals of Neurology · doi:10.1002/ana.410320505 · Cited by 222 · see citing works

Anti-A 42- and anti-A 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

Levites, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25410 · Cited by 207 · see citing works

Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration

Wilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202 · see citing works

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

Weksler, M. E., Relkin, N. R., Turkenich, R., LaRusse, S., Zhou, L., & Szabo, P. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00029-3 · Cited by 200 · see citing works

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

Farlow, M. R., Lahiri, D. K., Poirier, J., Davignon, J., Schneider, L., & Hui, S. L. (1998) · Neurology · doi:10.1212/wnl.50.3.669 · Cited by 199 · see citing works

Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice

Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. W., Hope, C. E., Hatcher-Martin, J. M., DiCarlo, G., Gottschall, W. P. E., Morgan, D., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00249-9 · Cited by 199 · see citing works

Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide

Agadjanyan, M. G., Ghochikyan, A., Petrushina, I., Vasilevko, V., Movsesyan, N., Mkrtichyan, M., Saing, T., & Cribbs, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1580 · Cited by 182 · see citing works

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

Black, R. S., Sperling, R. A., Safirstein, B., Motter, R. N., Pallay, A., Nichols, A., & Grundman, M. (2010) · Alzheimer Disease &amp; Associated Disorders · doi:10.1097/wad.0b013e3181c53b00 · Cited by 170 · see citing works

Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease

Monsonego, A., Maron, R., Zota, V. E., Selkoe, D. J., & Weiner, H. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191118298 · Cited by 162 · see citing works

Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Dodel, R. C., Hampel, H. J., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Büerger, K., Höft, C., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10253 · Cited by 161 · see citing works

Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice

Wilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., Ronan, V., Symmonds, K., Gordon, M. N., & Morgan, D. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0695-06.2006 · Cited by 154 · see citing works

Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition

Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G., & Golde, T. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00245-7 · Cited by 150 · see citing works

An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β Derivatives

Sigurdsson, E. M., Knudsen, E., Asuni, A. A., Fitzer‐Attas, C. J., Sage, D., Quartermain, D., Goñi, F., Frangione, B., & Wısnıewskı, T. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1344-04.2004 · Cited by 148 · see citing works

Autoantibodies to amyloid-? and Alzheimer's disease

Hyman, B. T., Smith, C. R., Buldyrev, I., Whelan, C. M., Brown, H., Tang, M., & Mayeux, R. P. (2001) · Annals of Neurology · doi:10.1002/ana.1061 · Cited by 144 · see citing works

Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice

Lemere, C. A. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00044-5 · Cited by 138 · see citing works

Immunotherapy Reduces Vascular Amyloid- in PDAPP Mice

Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., Gill, D., Basi, G., Schenk, D., Seubert, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2377-07.2008 · Cited by 133 · see citing works

Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy

Zaghi, J., Goldenson, B., Inayathullah, M., Lossinsky, A. S., Masoumi, A., Avagyan, H., Mahanian, M., Bernas, M. J., Weinand, M. E., Rosenthal, M. J., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0481-0 · Cited by 115 · see citing works

Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models

Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 113 · see citing works

Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides

Mruthinti, S., Buccafusco, J. J., Hill, W., Waller, J. L., Jackson, T. W., ZAMRINI, E. Y., & Schade, R. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.001 · Cited by 113 · see citing works

Autoantibodies to Amyloid β-Peptide (Aβ) are Increased in Alzheimer's Disease Patients and Aβ Antibodies Can Enhance Aβ Neurotoxicity: Implications for Disease Pathogenesis and Vaccine Development

Nath, A., Hall, E., Tuzova, M., Dobbs, M., Jones, M., Anderson, C., Woodward, J. G., Guo, Z., Fu, W., Kryscio, R. J., et al. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:1:29 · Cited by 107 · see citing works

A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ

Head, E., Pop, V., Vasilevko, V., Hill, M., Saing, T., Sarsoza, F. M., Nistor, M., Christie, L., Milton, S. C. F., Glabe, C. G., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0208-08.2008 · Cited by 106 · see citing works

SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain

Boche, D., & Nicoll, J. A. R. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00134.x · Cited by 104 · see citing works

High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation

Frenkel, D., Balass, M., Katchalski‐Katzir, E., & Solomon, B. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00003-x · Cited by 64 · see citing works

Immunization Therapy for Alzheimer Disease: A Comprehensive Review of Active Immunization Strategies

Tabira, T. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.220.95 · Cited by 59 · see citing works

Cerebral Amyloid-Beta Protein Accumulation with Aging in Cotton-Top Tamarins: A Model of Early Alzheimer's Disease?

Lemere, C. A., Oh, J., Stanish, H. A., Peng, Y., Pepivani, I., Fagan, A. M., Yamaguchi, H., Westmoreland, S. V., & Mansfield, K. G. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0677 · Cited by 56 · see citing works

Learning and Memory Deficits in APP Transgenic Mouse Models of Amyloid Deposition

Morgan, D. (2003) · Neurochemical Research · doi:10.1023/a:1023255106106 · Cited by 52 · see citing works

Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

Carty, N., Wilcock, D. M., Rosenthal, A., Grimm, J., Pons, J., Ronan, V., Gottschall, P. E., Gordon, M. N., & Morgan, D. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-11 · Cited by 49 · see citing works

APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology

Greenberg, B., Savage, M. J., Howland, D., Ali, S. M., Siedlak, S. L., Perry, G. L., Siman, R., & Scott, R. W. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00001-2 · Cited by 45 · see citing works

Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention

Tarawneh, R. M., & Holtzman, D. M. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847324 · Cited by 42 · see citing works

A$beta;1-15 is less immunogenic than A$beta;1-40/42 for intranasal immunization of wild-type mice but may be effective for ?boosting?

Leverone, J. F. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00754-5 · Cited by 39 · see citing works

Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated β -Amyloid 1-42 Peptide

Dickey, C. A., Morgan, D., Kudchodkar, S. B., Weiner, D. B., Bai, Y., Cao, C., Gordon, M. N., & Ugen, K. E. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717587 · Cited by 38 · see citing works

Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice

Karlnoski, R., Rosenthal, A., Kobayashi, D. T., Pons, J., Alamed, J., Mercer, M., Li, Q., Gordon, M. N., Gottschall, P. E., & Morgan, D. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4560-08.2009 · Cited by 34 · see citing works

Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide 1

Pan, W., Solomon, B., Maness, L. M., & Kastin, A. J. (2002) · Experimental Biology and Medicine · doi:10.1177/153537020222700808 · Cited by 34 · see citing works

Immunotherapeutic Strategies for Prevention and Treatment of Alzheimer's Disease

Solomon, B. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717550 · Cited by 27 · see citing works

Deglycosylated Anti-Aβ Antibody Dose–Response Effects on Pathology and Memory in APP Transgenic Mice

Karlnoski, R., Rosenthal, A., Alamed, J., Ronan, V., Gordon, M. N., Gottschall, P. E., Grimm, J., Pons, J., & Morgan, D. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9114-6 · Cited by 21 · see citing works

Differences in the immune response to long term A? vaccination in C57BL/6 and B6D2F1 mice

Seabrook, T. J. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.061 · Cited by 19 · see citing works

P1‐255: Direct observation of the kinetic mechanisms for Aß peptide aggregation: Towards elucidating Alzheimer plaque dissolution

Alcantar, N. A., Jimenez, J. P., & Morgan, D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.807 · Cited by 6 · see citing works

IC‐01‐02: Longitudinal PIB PET imaging of the appearance and accumulation of beta‐amyloid in cognitively normal middle and late life adults

Mintun, M. A., Vlassenko, A. G., Sheline, Y. I., & Morris, J. C. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.008 · Cited by 3 · see citing works

Behavioral phenotyping strategies for mutant mice

Crawley, J. N. (2008) · Neuron · doi:10.1016/j.neuron.2008.03.001 · Cited by 439 · see citing works

Animal Models of Alzheimer Disease

LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419 · see citing works

Glial contributions to neurodegeneration in tauopathies

Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409 · see citing works

Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis

Doens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348 · see citing works

Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes

Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298 · see citing works

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works

Immunotherapeutic Approaches for Alzheimer’s Disease

Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · see citing works

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241 · see citing works

Targeting microglia for the treatment of Alzheimer’s Disease

Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185 · see citing works

Clinical development of curcumin in neurodegenerative disease

Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1044981 · Cited by 179 · see citing works

Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · see citing works

Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems

Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124 · see citing works

Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery

Liu, Y.-H., Wang, Y.-R., Xiang, Y., Zhou, H.-D., Giunta, B., Mañucat-Tan, N. B., Tan, J., Zhou, X.-F., & Wang, Y.-J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8694-9 · Cited by 99 · see citing works

Amyloid-Related Imaging Abnormalities: An Update

Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99 · see citing works

Targeting Aβ and tau in Alzheimer's disease, an early interim report

Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89 · see citing works

Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: Insights and therapeutic approaches from periphery

Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78 · see citing works

Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions

Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66 · see citing works

Review: Experimental manipulations of microglia in mouse models of <scp>A</scp>lzheimer's pathology: activation reduces amyloid but hastens tau pathology

Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57 · see citing works

Nitric oxide‐mediated regulation of ‐amyloid clearance via alterations of <scp>MMP</scp>‐9/<scp>TIMP</scp>‐1

Ridnour, L. A., Dhanapal, S., Hoos, M., Wilson, J., Lee, J., Cheng, R. Y. S., Brueggemann, E. E., Hines, H. B., Wilcock, D. M., Vitek, M. P., et al. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12028 · Cited by 54 · see citing works

Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer’s disease pathology in TgSwDI and 3xTg mouse models

Goñi, F., Herline, K., Peyser, D., Wong, K., Ji, Y., Sun, Y., Mehta, P., & Wisniewski, T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-150 · Cited by 43 · see citing works

Progress of DN Treg cells in immunotherapy

Yin, L., & Chen, J. (2010) · 国际外科学杂志 · doi:10.3760/cma.j.issn.1673-4203.2010.12.014

Extrinsic factors associated with the response to immunotherapy in glioblastoma

Bi, H., & Zhang, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.018 · Cited by 5 · see citing works

The Resistance Mechanisms of Lung Cancer Immunotherapy

Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 88 · see citing works

DNA Damage Repair in Brain Tumor Immunotherapy

Zhao, S., Xu, B., Ma, W., Chen, H., Jiang, C., Cai, J., & Meng, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.829268 · Cited by 6 · see citing works

A Watershed Role of the Central Office of Investigator-initiated Clinical Trial in Cardiovascular Fields

Asakura, M., Kada, A., Yamamoto, H., et al. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.08.428